2FISHER B, GUNDUZ N, SAFFER EA. Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastases [ J]. Caneer Res, 1983, 43 (4): 1488-1492.
3ELDIDI MH, MONEER MM, KHALED HM, et al. Pathological assessment of the reponse of locally advanced breast cancer to ncoadjuvant chemotherapy and its implications for surgical management [J]. Surg Today, 2002, 30 (3) : 249 - 254.
5VICI P, CEBBIA G, GEBBIA V, et al. First line treatment with epirubicin and vinorelbine in metastatic breast cancer [J]. J Clin Oncol, 2002, 20:2689 - 2694.
6ANDERSON M. Doxorubiein versus methotreexate combined with cydophosphamide, 5 - fluorouraeil and tomozifen in post menopausal patients with advanced breast cancer randomized study with more than 10 years follow up [j]. EurJ Cancer, 1999, 35: 39-46.
7SMITH IE, WALSH G, JONES A, et aL High complete remission rates with primary neoajuvant infusional chemotherapy for large early breast cancer [J]. J Clin Oncol, 1995, 13: 424-429.
8HUNG WK, LAU Y, CHAN CM, et al. Experience of neoadjuvant chemotherapy for breast cancer at a public hospital: retrospective study [J]. Hong Kong Med J,2000, 6 (3) : 265 - 268.
9FANEYTE F, SCHRAMA JG, PETERSE JL, ctal,Breast cancer reponse to neoadjuvant chemotherapy:predictive markers and relation with outome [ J]. Br J Cancer, 2003, 88 (3): 406-412.
二级参考文献3
1左文述 徐忠法.现代乳腺肿瘤学[M].济南:山东科学技术出版社,1995.155-156.
2左文述，现代乳腺肿瘤学，1995年，155页
3P. Boré,R. Rahmani,J. Cantfort,C. Focan,J. P. Cano. Pharmacokinetics of a new anticancer drug, navelbine, in patients[J] 1989,Cancer Chemotherapy and Pharmacology(4):247～251
2Arriagada R,Le mg.Adjuvant radiotherapy in breast cancertreatment of lymph node areas[J].Acta oncol,2000,39:295 -305.
3Liu MF,Yang CY,Chao SC,et al.Distribution of double-negative (CD4^+ -CD8^-,DN)T subsets in blood and synovial fluid from patients with rheumatoid arthritis[J].Clin Rheumatol,1999,18(3):227 -231.
